Clinical Trials for Prinicipal Investigator: Lauren C Pinter-Brown

2 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-16-45 A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma Open
UCI-16-46 A Phase 1 dose-ranging study to investigate the safety, tolerability and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous, and intravenous administration in subjects with various lymphomas and leukemias Open